NCT02500680View on ClinicalTrials.gov

The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101)

PHASE1UnknownINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Influenza, Human
Interventions
BIOLOGICAL

MER4101

BIOLOGICAL

Inactivated Influenza Vaccine

Fluzone quadrivalent Influenza Vaccine

Trial Locations (1)

63104

Saint Louis University School of Medicine, St Louis

Sponsors
All Listed Sponsors
collaborator

Mercia Pharma Inc.

INDUSTRY

collaborator

Nova Laboratories Limited

INDUSTRY

collaborator

The Emmes Company, LLC

INDUSTRY

lead

Nova Immunotherapeutics Limited

INDUSTRY

NCT02500680 - The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101) | Biotech Hunter | Biotech Hunter